Table 2.
Comparison of treatment efficacy of atezolizumab plus bevacizumab in pretreated lenvatinib and pretreated non-lenvatinib groups.
| Pretreatment with lenvatinib (n = 20) |
Pretreatment with other than lenvatinib (n = 11) |
P value | |
|---|---|---|---|
| Age | 70.4 ± 2.05 | 72.0 ± 3.30 | .6524 |
| Sex (M/F) | 17/3 | 9/2 | .8177 |
| MVI (yes/no) | 2/18 | 2/9 | .3441 |
| Etiology (NASH/nonNASH) | 5/15 | 3/8 | .8902 |
| ALBI gGrade (1/2/3) | 4/16/0 | 3/8/0 | .6431 |
| Early tumor growth kinetics (RECIST) |
0.00625 ± 0.00205 | −0.00128 ± 0.00438 | .0369* |
| Early Tumor growth kinetics (mRECIST) |
0.00229 ± 0.0021 | −0.00322 ± 0.00269 | .1181 |
| Early Tumor growth kinetics ratio (RECIST) |
2.1482 ± 0.9418 | −0.4389 ± 1.1358 | .0918 |
| Early Tumor growth kinetics ratio (mRECIST) |
5.2945 ± 1.4975 | −1.1377 ± 1.7560 | .0126* |
| Reduction after tumor enlargement yes/no | 5/15 | 0/11 | .0269* |
| ORR (RECIST) | 21.0% | 9.09% | .3787 |
| DCR (RECIST) | 63.1% | 54.5% | .6431 |
| PFS (months) | 3.6 (1.3–6.3) | 2.7 (1.3–4.4) | .9448 |
| OS (months) | 11.6 (4.7–) | 11.4 (5.7–) | .9222 |
ALBI = albumin-bilirubin, DCR = disease control rate, MVI = macrovascular invasion, mRECIST = modified response evaluation criteria in solid tumors, NASH = nonalcoholic steatohepatitis, ORR = overall response rate, OS = overall survival, PFS = progression-free survival, RECIST = response evaluation criteria in solid tumors.
*Significant difference.